European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial

Trials

Volumn 9, Issue , 2008, Pages

  Hutchison, Colin A ^a,b   Cook, Mark ^a   Heyne, Nils ^c   Weisel, Katja ^c   Billingham, Lucinda ^b   Bradwell, Arthur ^b   Cockwell, Paul ^a,b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN LIGHT CHAIN;

ARTICLE; ARTIFICIAL KIDNEY; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTICENTER STUDY; MULTIPLE MYELOMA; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT RESPONSE;

EID: 53949120851     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-9-55     Document Type: Article

References (19)

1. Alexanian R Barlogie B Dixon D Renal failure in multiple myeloma. Pathogenesis and prognostic implications Arch Intern Med 1990, 150:1693-1695 10.1001/archinte.150.8.1693 2383164
2. Blade J Fernandez-Llama P Bosch F Montoliu J Lens XM Montoto S Cases A Darnell A Rozman C Montserrat E Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution Arch Intern Med 1998, 158:1889-1893 10.1001/ archinte.158.17.1889 9759684
3. Rayner HC Haynes AP Thompson JR Russell N Fletcher J Perspectives in multiple myeloma: Survival, prognostic factors and disease complications in a single centre between 1975 and 1988 Quart J Med 1991, 79:517-525 1946932
4. Sakhuja V Jha V Varma S Joshi K Gupta KL Sud K Kohli HS Renal involvement in multiple myeloma: A 10-year study Renal Failure 2000, 22:465-477 10.1081/JDI-100100888 10901184
5. Leung N Gertz MA Zeldenrust SR Rajkumar SV Dispensenzieri A Fervenza FC Kumar S Lacy MQ Lust JA Greipp PR Witzig TE Hayman SR Russel SJ Kyle RA Winters JL Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains Kidney Int 2008, 73(11):1282-8 10.1038/ki.2008.108 18385667
6. Hutchison CA Basnayake K Cook M Bradwell AR Cockwell P Free Light Chain Hemodialysis Increases Renal Recovery Rate and Improves Patient Survival in Patients with Cast Nephropathy Nephrol Dial Transplant Plus 2008, 1(Suppl 2):iI9a
7. Sanders PW Pathogenesis and treatment of myeloma kidney J Lab Clin Med 1994, 124(4):484-8 7930873
8. Chanan-Khan AA Kaufman JL Mehta J Richardson PG Miller KC Lonial S Munshi NC Schlossman R Tariman J Singhal S Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study Blood 2007, 109(6):2604-6 10.1182/ blood-2006-09-046409 17138816
9. Ludwig H Drach J Graf H Lang A Meran JG Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma Haematologica 2007, 92(10):1411-1414 10.3324/haematol.11463 17768111
10. Kastritis E Anagnostopoulos A Roussou M Gikka D Matsouka C Barmparousi D Grapsa I Psimenou E Barmias A Dimopoulos MA Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimes and the impact of novel agents Haematologica 2007, 92:546-549 10.3324/haematol.10759 17488666
11. Clark WF Stewart AK Rock GA Sternbach M Sutton DM Barrett BJ Heidenheim AP Garg AX Churchill DN Canadian Apheresis Group Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial Ann Intern Med 2005, 143(11):777-784 16330788
12. Ritz E Plasma exchange for acute renal failure of Myeloma - Logical, yet ineffective J Am Soc Nephrol 2006, 17:914-916 10.1681/ASN.2006080919
13. Clark WF Garg AX Plasma exchange for myeloma kidney: Cast (s) away? Kidney Int 2008, 73:1211-1213 10.1038/ki.2008.117 18480853
14. Hutchison CA Cockwell P Reid S Chandler K Mead GP Harrison J Hattersley J Evans ND Chappel MJ Cook M Goehl H Storr M Bradwell AR Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple Myeloma: In-vitro and in-vivo studies J Am Soc Nephrol 2007, 18:886-895 10.1681/ASN.2006080821 17229909
15. Bachmann U Schindler R Storr M Kahl A Joerres A Sturm I Combination of bortezomib-based cheometherapy and extracorpeal free light chain removal for treating cast nephropathy in multiple myeloma Nephrol Dial Transplant Plus 2008, 1:106-108
16. International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group British Journal of Haematology 2003, 121:749-757 10.1046/j.1365-2141.2003.04355.x 12780789
17. Pocock SJ Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials Biometrics 1975, 31:103-115 10.2307/2529712 1100130
18. Oakervee HE Popat R Curry N Smith P Morris C Drake M Agrawal S Stec J Schenkein D Esseltine DL Cavenagh JD PAD combination therapy (PS-341/ bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma) British J Haem 2005, 129:755-762 10.1111/ j.1365-2141.2005.05519.x
19. Durie BG Harousseau JL Miguel JS International uniform response criteria for multiple myeloma Leukemia 2006, 20:1467-1473 10.1038/sj.leu.2404284 16855634